References
- Kollmannsberger C., Peters H.D., Fink U. Chemotherapy in advanced pancreatic adenocarcinoma. Cancer Treat. Rev. 1998; 24: 133–156
- Permert J., Hafström L., Nygren P., Glimelius B. A systematic overview of chemotherapy effects in pancreatic cancer. Acta Oncol. 2001; 40: 361–370
- Burris H.A., 3rd, Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997; 15: 2403–2413
- Plunkett W., Huang P., Searcy C.E., Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin. Oncol. 1996; 23: 3–15
- Braakhuis B.J., van Dongen G.A., Vermorken J.B., Snow G.B. Preclinical in vivo activity of 2′2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res. 1991; 51: 211–214
- Kristjansen P.E., Quistorff B., Spang-Thomsen M., Hansen H.H. Intratumoral pharmacokinetic analysis by 19F-magnetic resonance spectroscopy and cytostatic in vivo activity of gemcitabine (dFdC) in two small cell lung cancer xenografts. Ann. Oncol. 1993; 4: 157–160
- Braakhuis B.J., Ruiz van Haperen V.W., Boven E., Veerman G., Peters G.J. Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin. Oncol. 1995; 22: 42–46
- Veerman G., Ruiz van Haperen V.W., Vermorken J.B., Noordhuis P., Braakhuis B.J., Pinedo H.M., Peters G.J. Antitumor activity of prolonged as compared with bolus administration of 2′2′-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother. Pharmacol. 1996; 38: 335–342
- Anderson H., Thatcher N., Walling J., Hansen H. A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br. J. Cancer 1996; 74: 460–462
- Eckel F., Lersch C., Assmann G., Schulte-Frohlinde E. Toxicity of a 24-hour infusion of gemcitabine in biliary tract and pancreatic cancer: a pilot study. Cancer Investig. 2002; 20
- Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., Filiberti A., Flechtner H., Fleishman S.B., de Haes J.C.J.M., Kaasa S., Klee M., Osoba D., Razavi D., Rofe P.B., Schraub S., Sneeuw K., Sullivan M., Takeda F. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for the use in international clinical trials in oncology. J. Natl Cancer Inst. 1993; 85: 365–376
- Glimelius B., Hoffman K., Sjödén P.O., Jacobsson G., Sellström H., Enander L.K., Linne T., Svensson C. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol. 1996; 7: 593–600
- Grunewald R., Abbruzzese J.L., Tarassoff P., Plunkett W. Saturation of 2′2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother. Pharmacol. 1991; 27: 258–262
- Pollera C.F. More is better but … how is best: are milligrams over hours better than grams over minutes? The case of gemcitabine. J. Clin. Oncol. 1997; 15: 2172–2174, Letter
- Schmid P., Akrivakis K., Flath B., Grosse Y., Sezer O., Mergenthaler H.G., Possinger K. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 1999; 10: 625–631
- Maarraouí A.M., MeKule C., Crawford E.D., Glode L.M. A phase I trial of 72 hour infusional gemcitabine in refractory genitourinary tumors using an accelerated titration dosing. Proc. Am. Soc. Clin. Oncol. 1999, abstr. 1334
- Kornek G.V., Pötter R., Selzer E., Schratter A., Ulrich-Pur H., Rogy M., Kraus G., Scheithauer W. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. Int. J. Radiat. Oncol. Biol. Phys. 2001; 49: 665–671
- Ward S., Morris E., Bansback N., Calvert N., Crellin A., Forman D., Larvin M., Radstone D. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer. Health Technol. Assess. 2001; 5: 1–79